Epigral

Which are the latest news on Epigral?

Why is Epigral Ltd falling/rising?

As of 05-Sep, Epigral Ltd's stock price is falling, currently at 1,219.05, reflecting a decline of 1.69% and significant underperformance over the past year with a return of -31.16%. The company's profits have also decreased by 37.3%, indicating poor long-term growth prospects and reduced investor interest.

As of 05-Sep, Epigral Ltd's stock price is falling, currently at 1,219.05, which reflects a decrease of 21.0 points or 1.69%. This decline is evident in today's performance, where the stock has underperformed its sector by 1.07%. Additionally, the stock reached an intraday low of Rs 1213.85, marking a drop of 2.11%.<BR><BR>Over the past year, Epigral Ltd has significantly underperformed the market, generating a return of -31.16% compared to the BSE500's positive return of 1.51%. This poor performance is compounded by a decline in profits, which have fallen by 37.3% over the same period. Furthermore, the company's operating profit has decreased at an annual rate of -5.48% over the last five years, indicating poor long-term growth prospects.<BR><BR>Investor participation has also waned, with delivery volume dropping by 28.55% against the 5-day average, suggesting reduced interest in the stock. Despite some positive factors, such as high management efficiency and a low Debt to EBITDA ratio, the overall sentiment remains negative due to the stock's substantial underperformance and declining financial metrics.

Who are in the management team of Epigral?

The management team of Epigral includes Maulik Jayantibhai Patel (Chairman & Managing Director), Kaushal Ashishbhai Soparkar (Managing Director), and several Executive and Independent Directors, responsible for the company's operations and strategic direction.

The management team of Epigral includes the following individuals:<BR><BR>1. **Maulik Jayantibhai Patel** - Chairman & Managing Director<BR>2. **Kaushal Ashishbhai Soparkar** - Managing Director<BR>3. **Karana Rameshbhai Patel** - Executive Director<BR>4. **Ankit Natwarlal Patel** - Executive Director<BR>5. **Darshan Anandbhai Patel** - Executive Director<BR>6. **Manubhai Khodidas Patel** - Independent Director<BR>7. **Nirali Bhavin Parikh** - Independent Director<BR>8. **Sanjay K Asher** - Independent Director<BR>9. **Kanubhai S Patel** - Independent Director<BR>10. **Raju Swamy** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Epigral do?

Epigral Ltd manufactures and sells Chlor Alkali and its derivatives, and trades agrochemical products within the Specialty Chemicals industry. As of June 2026, it reported net sales of 705 Cr and a net profit of 100 Cr, with a market cap of INR 5,234 Cr.

Overview:<BR>Epigral Ltd is engaged in the manufacturing and selling of Chlor Alkali and its derivatives, as well as trading agrochemical products, operating within the Specialty Chemicals industry and classified as a Small Cap company.<BR><BR>History:<BR>Epigral Ltd was incorporated in 2007 as Meghmani Finechem Limited and underwent a name change to Epigral Limited on August 4, 2023. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 705 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 100 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 5,234 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 43<BR>- Dividend Yield: 0.41%<BR>- Debt-Equity: 0.26<BR>- Return on Equity: 14.94%<BR>- Price to Book: 2.39<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Who are the peers of the Epigral?

Epigral's peers include Balaji Amines, Archean Chemical, Neogen Chemicals, Fineotex Chem, and others. In terms of management risk, growth, and capital structure, Fineotex Chem and Vishnu Chemicals stand out positively, while Epigral shows below-average growth and capital structure with a 1-year return of -33.76%.

Peers: The peers of Epigral are Balaji Amines, Archean Chemical, Neogen Chemicals, Fineotex Chem, Yasho Industries, Foseco India, Laxmi Organic, Vishnu Chemicals, Tatva Chintan, and Styrenix Perfor.<BR><BR>Quality Snapshot: Excellent management risk is observed at Fineotex Chem and Vishnu Chemicals, while Good management risk is found at Archean Chemical and Epigral. Average management risk is present at Balaji Amines, Neogen Chemicals, Yasho Industries, Foseco India, Laxmi Organic, Tatva Chintan, and Styrenix Perfor. Below Average growth is seen at Balaji Amines, Archean Chemical, Neogen Chemicals, Epigral, Yasho Industries, Laxmi Organic, and Tatva Chintan, while Good growth is noted at Fineotex Chem and Vishnu Chemicals. Excellent capital structure is exhibited by Balaji Amines, Archean Chemical, Fineotex Chem, Foseco India, and Laxmi Organic, while Average capital structure is found at Vishnu Chemicals, and Below Average capital structure is noted at Neogen Chemicals, Yasho Industries, and Epigral.<BR><BR>Return Snapshot: Fineotex Chem has the highest 1-year return at 113.31%, while Archean Chemical has the lowest at -26.00%. Epigral's 1-year return is -33.76%, which is lower than both of these peers. Additionally, the six-month return is negative for Archean Chemical and Styrenix Perfor.

How big is Epigral?

As of 31st August, Epigral Ltd has a market capitalization of 5,234.00 Cr, with recent net sales of 2,626.00 Cr and a net profit of 271.02 Cr over the last four quarters.

As of 31st August, <BR><BR>Market Cap: Epigral Ltd has a market capitalization of 5,234.00 Cr and is classified as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,626.00 Cr, while the sum of Net Profit for the same period is 271.02 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 2,221.43 Cr and Total Assets totaling 3,505.30 Cr.

Are Epigral Ltd latest results good or bad?

Epigral Ltd's latest results show a sequential profit recovery with a 23.21% increase in net profit quarter-on-quarter, but a 37.93% decline year-on-year indicates challenges. Overall, the results are mixed, reflecting operational improvements but concerns about year-on-year performance.

Epigral Ltd's latest results present a mixed picture. On one hand, the company has shown a sequential profit recovery, with net profit increasing by 23.21% quarter-on-quarter to ₹99.74 crores and operating margins expanding to 25.41%, the highest in recent history. This improvement is primarily attributed to enhanced operational efficiency and significantly reduced interest costs, which fell by 54.30% from the previous quarter.<BR><BR>However, when looking at year-on-year performance, the situation is less favorable. The net profit has declined by 37.93% compared to the same quarter last year, largely due to an exceptionally strong base in the previous year that included tax adjustments. Additionally, net sales decreased by 4.18% from the previous quarter, although they are still up 16.29% year-on-year.<BR><BR>Overall, while there are positive signs in terms of operational efficiency and margin improvement, the year-on-year profit decline and revenue softness indicate challenges that the company is currently facing. Therefore, the results can be viewed as good in terms of sequential recovery but concerning when compared to last year's performance.

Should I buy, sell or hold Epigral Ltd?

When is the next results date for Epigral Ltd?

The next results date for Epigral Ltd is 27 July 2026.

The next results date for Epigral Ltd is scheduled for 27 July 2026.

How has been the historical performance of Epigral?

Epigral has shown significant growth over the past five years, with net sales increasing from 828.60 Cr in Mar'21 to 2,550.13 Cr in Mar'25, and profit after tax rising from 100.84 Cr to 356.70 Cr. The company's total assets also grew from 1,448.70 Cr to 3,152.44 Cr, reflecting strong overall financial performance.

Answer:<BR>The historical performance of Epigral shows significant growth in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Epigral's net sales have increased from 828.60 Cr in Mar'21 to 2,550.13 Cr in Mar'25, demonstrating a strong upward trend. Total operating income followed a similar trajectory, rising from 828.60 Cr to 2,550.13 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 567.28 Cr in Mar'21 to 1,839.41 Cr in Mar'25, reflecting increased operational costs. Operating profit (PBDIT) has shown fluctuations, peaking at 725.93 Cr in Mar'25, while profit before tax reached 540.10 Cr, up from 160.86 Cr in Mar'21. Profit after tax has also risen significantly, from 100.84 Cr in Mar'21 to 356.70 Cr in Mar'25. The earnings per share (EPS) increased from 24.27 in Mar'21 to 82.91 in Mar'25, indicating improved profitability per share. On the balance sheet, total assets grew from 1,448.70 Cr in Mar'21 to 3,152.44 Cr in Mar'25, while total liabilities increased from 1,448.70 Cr to 3,152.44 Cr, showing a proportional rise in both assets and liabilities. Cash flow from operating activities improved from 229.00 Cr in Mar'21 to 440.00 Cr in Mar'25, contributing to a net cash inflow of 15.00 Cr in Mar'25, compared to an outflow of 11.00 Cr in Mar'24. Overall, Epigral has demonstrated robust growth in sales, profits, and asset base over the past five years.

Is Epigral technically bullish or bearish?

As of 14 October 2025, Epigral's technical trend is bearish with moderate strength, indicated by bearish signals from the MACD, Bollinger Bands, and daily moving averages, despite mixed signals from the KST and a mildly bullish perspective from Dow Theory.

As of 14 October 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Epigral is bearish with moderate strength. Key indicators driving this stance include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing bearish signals. The KST presents a mixed view with a bearish weekly signal but a bullish monthly signal, while the Dow Theory suggests a mildly bullish weekly perspective. Overall, the bearish trend is reinforced by the stock's recent performance, underperforming the Sensex across multiple time frames.

Is Epigral overvalued or undervalued?

As of October 6, 2025, Epigral is fairly valued with a PE ratio of 17.25 and strong growth potential, making it a solid investment compared to peers like Solar Industries and Gujarat Fluoroch, despite recent underperformance against the Sensex.

As of 6 October 2025, the valuation grade for Epigral has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 17.25, an EV to EBITDA of 11.40, and a PEG ratio of 0.26, indicating strong growth potential relative to its price.<BR><BR>In comparison to its peers, Epigral's valuation appears reasonable, especially when contrasted with Solar Industries, which has a PE ratio of 101.44, and Gujarat Fluoroch at 64.03. Notably, Godrej Industries is considered attractive with a PE of 37.84, further highlighting Epigral's competitive positioning within the specialty chemicals sector. While Epigral's recent stock performance has lagged behind the Sensex over the past year, it remains a solid investment opportunity given its fair valuation and strong return on capital employed of 24.11%.

Who are the top shareholders of the Epigral?

The top shareholders of Epigral include Ashishbhai Natawarlal Soparkar with 14.65%, individual investors with 16.98%, mutual funds holding 4.48%, and foreign institutional investors at 3.01%. The largest public shareholder is HSBC Focused Fund with a 2.77% stake.

The top shareholders of Epigral include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ashishbhai Natawarlal Soparkar, with a stake of 14.65%. Additionally, individual investors collectively hold 16.98% of the shares. Among institutional investors, mutual funds hold 4.48% through 8 schemes, while foreign institutional investors (FIIs) hold 3.01% across 83 entities. The highest public shareholder is HSBC Focused Fund, which has a holding of 2.77%.

Has Epigral declared dividend?

Epigral Ltd has declared a 25% dividend, amounting to $2.5 per share, with an ex-date of February 7, 2025. The dividend yield is 0.41%, and while the company has shown strong total returns over the past year and two years, it experienced negative returns in the last six months.

Epigral Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 07 Feb 25<BR><BR>Dividend Yield: 0.41%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Epigral experienced a price return of -13.45%, a dividend return of 0.12%, resulting in a total return of -13.33%.<BR><BR>Over the past year, the company achieved a price return of 41.9%, with a dividend return of 0.57%, leading to a total return of 42.47%.<BR><BR>In the 2-year period, Epigral saw a price return of 64.87% and a dividend return of 0.87%, culminating in a total return of 65.74%.<BR><BR>For the 3-year period, the price return was 20.62%, the dividend return was 1.03%, resulting in a total return of 21.65%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, Epigral reported no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Epigral Ltd has declared a dividend and has shown strong total returns over the 1-year and 2-year periods, despite negative returns in the 6-month timeframe. The dividend yield indicates a modest return relative to the stock price, reflecting the company's commitment to returning value to shareholders.